ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Real World Data Support International Consenus Guidelines on Management of CMV after Kidney Transplantation

A. Asberg, G. B. Kro, A. V. Reisæter, A. Hartmann, K. Midtvedt

Oslo University Hospital - Rikshospitalet, Oslo, Norway

Meeting: 2019 American Transplant Congress

Abstract number: B230

Keywords: Cytomeglovirus, Ganciclovir, Kidney transplantation, Prophylaxis

Session Information

Session Name: Poster Session B: Kidney Infections

Session Type: Poster Session

Date: Sunday, June 2, 2019

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: Cytomegalovirus (CMV) naïve kidney transplant recipients (R-) transplanted with an organ from a CMV positive donor (D+) are at high risk for CMV disease. For the D+R- recipients the updated TTS International Consensus Guidelines on CMV Management depicts no preference with regard to prophylactic or preemptive preventive approach, provided an adequate surveillance of CMV PCR when the preemptive approach is used. Our center switched from a preemptive approach, with active surveillance, to routinely 6 month valganciclovir (vGCV) prophylaxis in 2011. Whether the long-term outcomes are different with these alternate strategies is not known.

*Methods: Altogether, complete national data from 410 D+R- kidney transplant recipients were available (2007-2010; 151 recipients with active surveillance receiving preemptive vGCV therapy vs. 2011-2017; 260 recipients whom received vGCV prophylaxis from time of engraftment; 900 mg once daily, adjusted for renal function). All 1660 R+ kidney transplant recipients in the period 2007-2017 served as controls for the effect of the two time era. Long-term graft and patient outcomes were retrieved from the Norwegian Renal Registry. All patients have given written informed consent for use of their data.

*Results: The actuarial 5 years patient survival in D+R- patients was not different with preemptive compared with prophylaxis treatment; preemptive 89% [95% CI: 85%-95%] vs. prophylactic 86% [81%-92%] (Figure 1, P=0.23). Also, the crude and death censored graft survival were similar; 85% [80%-90%] vs. 77% [71%-84%] (P=0.13) and 92% [88%-97%] vs. 87% [82%-93%] (P=0.29), respectively. In R+ patients the corresponding 5 years patient and death censored graft survival rates remained unchanged in the two time eras; 86% [83%-88%] vs. 86% [83%-88%] (P=0.69) and 93% [91%-95%] vs. 93% [91%-95%] (P=0.77), respectively.

*Conclusions: The long-term outcomes of preemptive therapy or prophylaxis for CMV prevention in high-risk kidney transplant recipients were similar. These “real world” findings support the international consensus guidelines which recommend the use of either strategy as preferred by the different transplant centers.

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Asberg A, Kro GB, Reisæter AV, Hartmann A, Midtvedt K. Real World Data Support International Consenus Guidelines on Management of CMV after Kidney Transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/real-world-data-support-international-consenus-guidelines-on-management-of-cmv-after-kidney-transplantation/. Accessed June 1, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences